Hospital acquired infections: The different common sources of infection, their routes of spread and the growing antimicrobial resistance. Also includes a discussion on hospital Infection prevention and control guidelines and the universal and standard precautions.
Hospital acquired infections: The different common sources of infection, their routes of spread and the growing antimicrobial resistance. Also includes a discussion on hospital Infection prevention and control guidelines and the universal and standard precautions.
Hand washing, also known as hand hygiene, is the act of cleaning hands for the purpose of removing soil, dirt, and microorganisms. If water and soap is not available, hands can be cleaned with ash instead. Medical hand hygiene refers to hygiene practices related to medical procedures.
A short brief on 'Hospital Acquired Infections' (HAI) or 'Nosocomial Infection' (NI) for M Phil, MPH and Advance Course in Hospital Management/ Administration
Central-Line-Associated Bloodstream Infections (CLABSI) pause a major health problem in hospitalized patients. This disease is associated with people with a central line/tube inserted through the skin into the large vein, which can be used to give medicines, fluids, nutrients, or blood products to patients in critical conditions. The disease occurs when microbes enter through the central line invading the bloodstream.
Hand washing, also known as hand hygiene, is the act of cleaning hands for the purpose of removing soil, dirt, and microorganisms. If water and soap is not available, hands can be cleaned with ash instead. Medical hand hygiene refers to hygiene practices related to medical procedures.
A short brief on 'Hospital Acquired Infections' (HAI) or 'Nosocomial Infection' (NI) for M Phil, MPH and Advance Course in Hospital Management/ Administration
Central-Line-Associated Bloodstream Infections (CLABSI) pause a major health problem in hospitalized patients. This disease is associated with people with a central line/tube inserted through the skin into the large vein, which can be used to give medicines, fluids, nutrients, or blood products to patients in critical conditions. The disease occurs when microbes enter through the central line invading the bloodstream.
Infection Control Guidelines in Tuberculosis [compatibility mode]drnahla
Infection Control Guidelines in Tuberculosis
Dr. NAHLA ABDEL KADERوMD, PhD.
INFECTION CONTROL CONSULTANT, MOH
INFECTION CONTROL CBAHI SURVEYOR
Infection Control Director, KKH.
Immunization of children with cancer is a burning topic. Not only concerned parents but also paediatric oncologists have so many questions and queries regarding this matter. This presentation will try to answer those questions with the help of recent and updated guidelines on immunization of both developed and developing countries.
In the last 42 days, Six deaths and 421 cases of swine flu have been reported from 28 districts of the state. Here's what you need to know about the disease.
Similar to Immunization of Healthcare Professionals (20)
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
1. OCCUPATIONAL HEALTH
& IMMUNIZATION OF HCP
Dr. Faisal Al Haddad
Consultant Family Medicine &
Occupational Health
Director of Saudi Board Program
CBAHI Surveyor
2. Immunization Schedule for HCP
Vaccine Indication Schedule
Hepatitis A Laboratory & primate worker 2doses of 1 mL IM at 0,
6 months
Hepatitis B Occupational exposure to
blood, blood products, or
bodily secretions
3doses of 1 mL IM at 0,
1 & 6-12 months
Influenza Persons attending high-risk
patients (e.g. elderly(
Inactivated vaccine:
1dose of 0.5 mL IM
annually
Live attenuated vaccine:
Intranasal dose of 0.2 ml
annually
3. Immunization Schedule for HCP
Vaccine Indication Schedule
MMR Adults born after 1957 with no proof of
immunity:
•documented vaccination with 2 doses
•laboratory evidence of immunity
•laboratory confirmation of disease
2doses of 0.5 mL SC
at 0 & at least 1 month
later
Polio Laboratory and other HCP who come in
contact with live virus
3doses of 0.5 mL SC:
•1st
two doses 4-8
weeks apart
•3rd
dose 6-12 months
after the 2nd
dose.
4. Immunization Schedule for HCP
Vaccine Indication Schedule
Varicella Adults with no proof of immunity:
•laboratory evidence of immunity
•HX of clinically diagnosed or
verified varicella/zoster
•documentation of vaccination
2doses of 0.5 mL SC
at time 0 weeks & 4-8
weeks later
Tdap HCP with direct patient contact 0.5mL IM one-time
dose
5. Influenza Vaccination
HCP must receive the vaccine or sign a declination after
reading the benefits of receiving vaccine versus risks to self,
patients and others by not receiving the vaccine.
If HCP refuses the influenza vaccine, it is mandatory that HCP
wear a barrier mask during influenza season when providing
direct patient care.
Methods increasing vaccination rates:
– Monetary incentive to receive the vaccine.
– Providing the vaccine at convenient times and locations.
– Receiving the vaccine as a condition of employment.
6. Influenza Vaccination
Vaccination against influenza is recommended for all HCP.
It takes about 2 weeks after vaccination for antibodies to
develop that protect against influenza virus infection.
Vaccines can be offered from September to March.
Inactivated trivalent vaccine (TIV(:
– > 6 months old (healthy people, chronic medical conditions(
– One dose of 0.5 mL IM annually
7. Influenza Vaccination
Live attenuated influenza vaccine (LAIV(:
– Healthy people 2 to 49 years of age who are not pregnant
– Intranasal dose of 0.2 ml annually
Avoid use of LAIV among HCP or other close contacts of
severely immunocompromised persons.
HCP who receive LAIV should not provide care for severely
immune-suppressed patients for 7 days after vaccination.
8. Influenza Vaccination
If influenza outbreak occurs, unvaccinated staff should be re-
offered influenza vaccinations
If an outbreak is caused by a strain of influenza virus that is not
well matched by the vaccine for that season, chemoprophylaxis
should be considered for all employees, regardless of their
vaccination status.
9. Work Restrictions for HCP with
Infectious Diseases
Disease/Problem Work Restriction Duration
Conjunctivitis Restrict from patient
contact & contact with the
patient's environment
Until discharge ceases
CMV infections No restriction
Diarrheal diseases
Acute stage Restrict from patient
contact, contact with the
patient's environment, or
food handling
Until symptoms resolve
Convalescent stage Restrict from care of high-
risk patients
Until symptoms resolve
10. Work Restrictions for HCP With
Infectious Diseases
Disease/Problem Work Restriction Duration
Diphtheria Exclude from duty Until antimicrobial
therapy completed & 2
cultures obtained 24 hrs
apart are negative
Enteroviral
infections
Restrict from care of
infants, neonates, and
immunocompromised
patients and their
environments
Until symptoms resolve
Hepatitis A Restrict from patient
contact, contact with
patient's environment &
food handling
Until 7 days after onset
of jaundice
11. Work Restrictions for HCP With
Infectious Diseases
Disease/Problem Work Restriction Duration
Hepatitis B
Personnel with
HBsAg who do not
perform EPP
No restriction; Standard
Precautions should always be
observed
Personnel with
HBeAg who perform
EPP
Do not perform EPP until expert
review panel recommend
procedures the worker can perform
Until HBe Ag
is negative
Hepatitis C No recommendation
12. Work Restrictions for HCP With
Infectious Diseases
Disease/Problem Work Restriction Duration
Herpes simplex
Genital No restriction
Hands (herpetic
whitlow(
Restrict from patient
contact and contact with
the patient's environment
Until lesions heal
Orofacial Evaluate for need to restrict
from care of high-risk
patients
HIV Do not perform EPP until expert review panel
recommend procedures the worker can perform
13. Work Restrictions for HCP With
Infectious Diseases
Disease/Problem Work
Restriction
Duration
Meningococcal
infections
Exclude from
duty
Until 24 hours after start of
effective therapy
Pediculosis Restrict from
patient contact
Until treated and observed to be
free of adult and immature lice
Pertussis Exclude from duty From beginning of catarrhal stage
through 3rd
week after onset of
paroxysms or until 5 days after start
of effective antimicrobial therapy
Scabies Restrict from
patient contact
Until cleared by medical evaluation
14. Work Restrictions for HCP With
Infectious Diseases
Disease Work Restriction Duration
Staphylococcus
aureus infection
Active (draining
skin lesions(
Restrict from contact with
patients and patients'
environment or food handling
Until lesions have
resolved
Carrier state No restriction, unless personnel
are epidemiologically linked to
transmission of the organism
Streptococcal
infection, group A
Restrict from patient care,
contact with patient's
environment, or food handling
Until 24 hours
after adequate
treatment started
15. Work Restrictions for HCP With
Infectious Diseases
Disease Work Restriction Duration
Measles Exclude from duty Until 7 days after the rash
appears
Mumps Exclude from duty Until 9 days after onset of
parotitis
Rubella Exclude from duty Until 5 days after rash
appears
Varicella Exclude from duty Until all lesions dry and crust
TB Exclude from duty Until proved noninfectious
18. Varicella Post Exposure Management
Unvaccinated susceptible personnel exposed to varicella:
Exclude the person from duty from the 10th day after exposure
through the 21st day after exposure or until all lesions are dry and
crusted if varicella occurs.
Vaccinated personnel exposed to varicella:
Serological testing immediately after exposure to assess the
presence of antibody.
If seronegative, exclude the person from duty from day 10 through day
21 postexposure.
If fever, URT symptoms, or rash develop, then exclude the person from
duty until all lesions are dry and crusted
19. Varicella Post Exposure Management
Consider administering the vaccination for exposed
unvaccinated personnel without documented immunity. The
efficacy of postexposure vaccination is unknown.
VZIG use is considered for immunocompromised or pregnant
workers postexposure.
If VZIG is used, extend the time that the worker is excluded
from duty from 21 days to 28 days postexposure.
20. Meningococcal Disease Post Exposure
Management
Exposed personnel do not need to be excluded from duty.
PEP is advised for persons who have had intensive, unprotected
contact with infected patients.
Unprotected means without wearing a mask
Intensive contact include:
– mouth-to-mouth resuscitation
– endotracheal intubation
– endotracheal tube management or
– close examination of the oropharynx
21. Meningococcal Disease Post Exposure
Management
Prophylactic therapy should be administered immediately after
the unprotected exposure.
Current recommended regimens:
– Rifampin 600 mg PO BID for 2 days
– Single dose of ciprofloxacin 500 mg PO or
– Single dose of ceftriaxone 250 mg IM.
Rifampin & ciprofloxacin are not recommended for pregnant
women.
22. MMR Post Exposure Management
Measles vaccine should be administered to susceptible HCP
who have had contact with a measles patient within 3 days of the
exposure (or IG within 6 days of exposure) to modify severity of
infection
Mumps vaccine and IG are not proven to prevent infection after
exposure.
Rubella vaccine and IG are not proven to prevent infection after
exposure.
23. MMR Post Exposure Management
Susceptible personnel who are exposed to measles need to be
excluded from duty 5 days after the first exposure to 21 days
after the last exposure.
Susceptible personnel who are exposed to mumps need to be
excluded from duty the 9th
day after the first exposure to the 26th
day after the last exposure.
Susceptible personnel who are exposed to rubella need to be
excluded from duty from the 7th
day after the first exposure
through the 21st
day after the last exposure.
24. Pertussis Post Exposure Management
PEP is indicated for personnel exposed to pertussis.
The regimen used is either:
– Erythromycin 500 mg QID 14 days
– One tab of trimethoprim-sulfamethoxazole BID 14 days
Exposed personnel do not need to be excluded from duty.
Personnel in whom symptoms develop should be excluded until
5 days after the start of appropriate therapy.
25. Practice
A food service worker is diagnosed with Hepatitis A. How long
should this employee be on work restrictions?
a. Until 14 days after symptoms resolve
b. Until 7 days after onset of jaundice
c. Until 14 days after onset of jaundice
d. Until 10 days after symptoms resolve
26. Practice
ACIP recommends all of the following immunizations be provided
to healthcare personnel except:
a. Hepatitis A and B vaccines
b. Influenza vaccine
c. Measles, mumps, and rubella (MMR) and varicella-zoster
vaccines (if not immune)
d. BCG
27. Practice
An employee who is not immune to varicella-zoster was exposed
to a patient with active chickenpox. How long must the employee
remain on work restrictions?
a. Until evaluated by a physician
b. From day 10 after exposure to day 21 after exposure
c. No work restriction is necessary if no signs and symptoms are
present
d. At the discretion of the hospital infectious disease physician
28. Practice
The IP is reviewing the immunization records of healthcare personnel at their
facility and discovers that employees born before 1957 do not have any
record of receiving MMR vaccine. What should she recommend to the
Human Resources Director regarding employees born before 1957?
a. They are considered immune and do not require follow-up
b. They should receive two doses of the vaccine 4 weeks apart
c. They are only required to provide proof of immunity to measles
d. They are required to provide proof of immunity mumps, measles & rubella
29. Practice
A patient in the Emergency Room is diagnosed with bacterial
meningitis due to Neisseria meningitidis. The patient was not
properly isolated, and a number of employees entered her room
without wearing a mask. Which employee should receive PEP?
a. The phlebotomist who drew blood on the patient
b. The respiratory therapist who intubated the patient
c. The radiology technician that performed the chest radiograph
d. The employee from admissions that registered the patient
30. Practice
OSHA mandates that which of the following vaccines be provided
at no cost to healthcare providers and others at risk for blood and
body fluid exposure?
a. Hepatitis A
b. Hepatitis B
c. BCG
d. Meningococcal
31. Practice
Which of the following is not proof of measles immunity for
healthcare personnel?
a. Documentation of vaccination with two doses of live measles
virus-containing vaccine
b. Laboratory evidence of immunity
C. Born after 1957
d. Laboratory confirmation of disease